Abstract
Cancer metastasis to the bone develops commonly in patients with a variety of malignancies, and is a major cause of morbidity and diminished quality of life in a significant proportion of cancer patients. The effective treatment of bone metastasis requires cooperation between medical, surgical and radiation oncologists. Radiotherapy, either in the form of targeted external beam radiation therapy, or systemic administration of radionuclides, plays a central role in treatment of symptomatic bone metastases. The appropriate external beam treatment techniques, dose and fractionation regimens for the treatment of symptomatic, localized bone metastasis have been established in prospective clinical trials. Large-field, hemi-body irradiation has been utilized for treatment of symptoms related to more widely disseminated bone metastases, but has been associated with substantial toxicity. Strontium-89 and Samarium-153 are widely available systemically administered radionuclides that are useful for the treatment of widely disseminated disease, and have largely supplanted the use of hemi-body irradiation. Combined with appropriate medical and surgical interventions, as well as the appropriate use of analgesics, radiotherapy is a well-tolerated and highly effective treatment for the palliation of symptomatic bone metastases.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Plunkett, T. A., & Rubens, R. D. (1999). The biology and management of bone metastases. Critical Reviews in Oncology/Hematology, 31, 89–96.
Tubiana-Hulin, M. (1991). Incidence, prevalence and distribution of bone metastases. Bone, 12(Suppl 1), S9–S10.
Foley, K. M. (1985) The treatment of cancer pain. New England Journal of Medicine, 313, 84–95.
Tong, D., Gillick, L., & Hendrickson, F. R. (1982). The palliation of symptomatic osseous metastases: Final results of the Study by the Radiation Therapy Oncology Group. Cancer, 50, 893–899.
Townsend, P. W., Rosenthal, H. G., Smalley, S. R., Cozad, S. C., & Hassanein, R. E. (1994). Impact of postoperative radiation therapy and other perioperative factors on outcome after orthopedic stabilization of impending or pathologic fractures due to metastatic disease. Journal of Clinical Oncology, 12, 2345–2350.
O’Sullivan, B., Davis, A. M., Turcotte, R., Bell, R., Catton, C., Chabot, P., et al. (2002). Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial. Lancet, 359, 2235–2241.
Vargha, Z. O., Glicksman, A. S., & Boland, J. (1969). Single-dose radiation therapy in the palliation of metastatic disease. Radiology, 93, 1181–1184.
Wu, J. S., Wong, R., Johnston, M., Bezjak, A., & Whelan, T. (2003). Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. International Journal of Radiation Oncology, Biology, Physics, 55, 594–605.
Steenland, E., Leer, J. W., van Houwelingen, H., Post, W. J., van den Hout, W. B., Kievit, J., et al. (1999). The effect of a single fraction compared to multiple fractions on painful bone metastases: A global analysis of the Dutch Bone Metastasis Study. Radiotherapy and Oncology, 52, 101–109.
van der Linden, Y. M., Lok, J. J., Steenland, E., Martijn, H., van Houwelingen, H., Marijnen, C. A., et al. (2004). Single fraction radiotherapy is efficacious: A further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment. International Journal of Radiation Oncology, Biology, Physics, 59, 528–537.
Bone Pain Trial Working Party (1999). 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: Randomised comparison with a multifraction schedule over 12 months of patient follow-up. Radiotherapy and Oncology, 52, 111–121.
Hartsell, W. F., Scott, C. B., Bruner, D. W., Scarantino, C. W., Ivker, R. A., Roach, M., et al. (2005). Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. Journal of the National Cancer Institute, 97, 798–804.
Poulter, C. A., Cosmatos, D., Rubin, P., Urtasun, R., Cooper, J. S., Kuske, R. R., et al. (1992). A report of RTOG 8206: A phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases. International Journal of Radiation Oncology, Biology, Physics, 23, 207–214.
Salazar, O. M., Sandhu, T., da Motta, N. W., Escutia, M. A., Lanzos-Gonzales, E., Mouelle-Sone, A., et al. (2001). Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: A randomized Phase III trial of the International Atomic Energy Agency (IAEA). International Journal of Radiation Oncology, Biology, Physics, 50, 765–775.
Blake, G. M., Zivanovic, M. A., McEwan, A. J., & Ackery, D. M. (1986). Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate. European Journal of Nuclear Medicine, 12, 447–454.
Lewington, V. J., McEwan, A. J., Ackery, D. M., Bayly, R. J., Keeling, D. H., Macleod, P. M., et al. (1991). A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. European Journal of Cancer, 27, 954–958.
Porter, A. T., McEwan, A. J., Powe, J. E., Reid, R., McGowan, D. G., Lukka, H., et al. (1993). Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. International Journal of Radiation Oncology, Biology, Physics, 25, 805–813.
Buchali, K., Correns, H. J., Schuerer, M., Schnorr, D., Lips, H., & Sydow, K. (1988). Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. European Journal of Nuclear Medicine, 14, 349–351.
Quilty, P. M., Kirk, D., Bolger, J. J., Dearnaley, D. P., Lewington, V. J., Mason, M. D., et al. (1994). A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiotherapy and Oncology, 31: 33–40.
Laing, A. H., Ackery, D. M., Bayly, R. J., Buchanan, R. B., Lewington, V. J., & McEwan A. J. (1991). Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. British Journal of Radiology, 64, 816–822.
Serafini, A. N., Houston, S. J., Resche, I., Quick, D. P., Grund, F. M., Ell, P. J., et al. (1998). Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial. Journal of Clinical Oncology, 16, 1574–1581.
Sartor, O., Reid, R. H., Hoskin, P. J., Quick, D. P., Ell, P. J., Coleman, R.E, et al. (2004). Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology, 63, 940–945.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lin, A., Ray, M.E. Targeted and systemic radiotherapy in the treatment of bone metastasis. Cancer Metastasis Rev 25, 669–675 (2006). https://doi.org/10.1007/s10555-006-9025-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10555-006-9025-z